Latest Conference Articles

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the current burden of C. diff infection and recurrent C. diff infection.

The combination therapy of ibrutinib and venetoclax was superior to chlorambucil and obinutuzumab in terms of undetectable minimal residual disease responses in elderly or unfit patients with previously untreated chronic lymphocytic leukemia.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the risk factors for C. diff infection and recurrent C. diff infection.

In a phase 1b trial, the combination therapy of acalabrutinib, venetoclax, and rituximab had a 100% clinical response rate and was well-tolerated in patients with treatment-naïve mantle cell lymphoma.

A panel recently re-convened recently to develop guidance for AmpC-bearing gram-negative pathogens.

The long-acting antiretroviral therapy is intended to replace antiretroviral regimens for individuals who are virologically suppressed.

Pharmacists can help patients manage their medications and any adverse effects, and can also educate patients about their condition and treatments.

In this video, Dr. Sherman recommends strategies for solving drug therapy related problems common to long-acting antiretroviral agents, such as missed doses, adverse drug reactions and drug–drug interactions.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the relationship between gut microbiome and C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discusses the current treatment strategies for C. diff infection and recurrent C. diff infection, as well as the efficacy and safety of these treatments.

In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, explains what the gut-brain axis is and how microbiome impacts this connection.

In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the role of the microbiome in overall patient health and recurrent Clostridioides difficile infection.

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections.

Fulvestrant is also the only SERD approved for patients with breast cancer, according to the researchers.

Results of analysis suggest that pharmacists can play a crucial role in increasing annual vaccinations.

Pharmacists can play an important role in avoiding common medication errors for patients receiving direct oral anticoagulants.

In this video, Dr. Sherman describes the pharmacology and pharmacokinetics of cabotegravir and rilpivirine as long acting injectable antiretroviral therapy agents.

In this video, Dr. Sherman describes what pre-exposure prophylaxis is and how long-acting injectable antiretroviral agents can help to prevent HIV and may even improve adherence.

The investigators found that modeling was a cost-effective method for determining the functionality of the proposed blueprint by transforming it into a physical space.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

Although barcode scanning during product verification has greatly improved the safety of medication dispensing operations, many products aren’t easily incorporated into traditional dose preparation processes, including medications manually dispensed in oral syringes.

Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) intended for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

The investigators found that the ability to track the status of a medication in real-time may assist with communication gaps between departments and facilitate patient safety improvements.

The findings of a study showed that the percentage of “I am satisfied with my job” respondents increased by 28.7% for those in the pilot and decreased by 17.9% for those not in the pilot.

The investigators said that there were no new safety signals identified, and no reported instances of tumor lysis syndrome.